Boehringer Ingelheim

C. H. Boehringer Sohn AG & Co. KG

Type	Private
Industry	Pharmaceuticals
Founded	Ingelheim am Rhein, Germany (1885 (1885))
Headquarters	Ingelheim, Germany
Area served	Worldwide
Key people	Andreas Barner, Chairman of the board Hubertus von Baumbach, board member Wolfgang Baiker, board member Allan Hillgrove, board member Joachim Hasenmaier, board member Andreas Neumann, board member Claudia Westphal, board member Rudolf Westphal, board member Michel Pairet, board member
Products	Human Pharmaceuticals and Animal Health
Revenue	€13.3 billion (2014)
Operating income	€2.14 billion (2014)
Total assets	€20.05 billion(2014)
Total equity	€8.111 billion(2014)
Number of employees	47,744
Website	www.boehringer-ingelheim.com

C.H. Boehringer Sohn AG & Ko. KG is the parent company of Boehringer Ingelheim GmbH, which was founded in 1885 by Albert Boehringer in Ingelheim am Rhein, Germany. The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Still headquartered in Ingelheim, it operates globally with 146 affiliates and more than 47,700 employees. The company's key assets of interest are: respiratory diseases, metabolism, immunology, oncology and diseases of the central nervous system. Boehringer Ingelheim is a full member of the European Federation of Pharmaceutical Industries and Associations EFPIA. The corporate logo of Boehringer Ingelheim depicts a stylized rendition of the central section of the imperial palace of Charlemagne.

Boehringer Ingelheim works in human pharmaceuticals, animal health and biopharmaceuticals. The group consists of 145 affiliated companies with 47,500 employees in 2015 in all continents. Research and development facilities were in five sites and 20 production plants in 13 countries. The research and development facilities are located in Biberach (Germany), Ridgefield (Connecticut), Vienna, Kobe, and Milan. Over 8,000 employees work for Boehringer Ingelheim in research and development.

In July 2015, the company sold its Roxane business to Hikma Pharmaceuticals Plc for $2.65 billion ($1.18 billion in cash and issue 40 million new Hikma shares). The company also agreed to make cash payments of up to $125 million based on performance milestones. On the same day the company announced it would partner with Hanmi Pharmaceutical to develop and commercialise HM61713, a third generation treatment for EGFR mutation-positive lung cancer. Boehringer also terminated its collaboration with Vitae Pharmaceuticals on a new BACE program for Alzheimer's.